CLINAC SUMMARY
Clinac® BPO 7 (benzoyl peroxide) is a topical preparation containing 7% benzoyl peroxide as the active ingredient in a gel vehicle containing purified water, propylene glycol, Acrysorb™ (brand of acrylates copolymer), PEG-400, carbomer 940, disodium EDTA, and sodium hydroxide.
Clinac® BPO 7 is indicated for the topical treatment of mild to moderate acne vulgaris. Clinac® BPO 7 may be used with other acne treatments including retinoic acid products, antibiotics and sulfur/salicylic acid containing preparations.
|
NEWS HIGHLIGHTSMedia Articles Related to Clinac (Benzoyl Peroxide Topical)
Health Tip: What's Triggering My Acne?
Source: MedicineNet Acne Specialty [2009.06.24]
Title: Health Tip: What's Triggering My Acne?
Category: Health News
Created: 6/24/2009 7:00:00 AM
Last Editorial Review: 6/24/2009
New Laser Combo Therapy Zaps Acne
Source: MedicineNet Acne Specialty [2009.03.09]
Title: New Laser Combo Therapy Zaps Acne
Category: Health News
Created: 3/7/2009 2:00:00 AM
Last Editorial Review: 3/9/2009
Acne Cream Not Linked to Raised Death Risk
Source: MedicineNet tretinoin Specialty [2009.01.26]
Title: Acne Cream Not Linked to Raised Death Risk
Category: Health News
Created: 1/24/2009 2:00:00 AM
Last Editorial Review: 1/26/2009
FDA OKs New Acne Gel Epiduo
Source: MedicineNet adapalene Specialty [2009.01.07]
Title: FDA OKs New Acne Gel Epiduo
Category: Health News
Created: 1/7/2009
Last Editorial Review: 1/7/2009
Acne (Pimples)
Source: MedicineNet Boils Specialty [2008.07.16]
Title: Acne (Pimples)
Category: Diseases and Conditions
Created: 12/31/1997
Last Editorial Review: 7/16/2008
Published Studies Related to Clinac (Benzoyl Peroxide Topical)
Adapalene-benzoyl peroxide, a unique fixed-dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double-blind, controlled study in 1670 patients. [2009.05.21]
Summary Background Combination therapy utilizing agents with complementary mechanisms of action is recommended by acne guidelines to help simultaneously target multiple pathogenic factors. A unique, topical, fixed-dose combination gel with adapalene 0.1% and benzoyl peroxide (BPO) 2.5% has recently been developed for the once-daily treatment of acne...
Comparison of 2 clindamycin 1%-benzoyl peroxide 5% topical gels used once daily in the management of acne vulgaris. [2009.05]
Combination therapy for the topical treatment of acne vulgaris using benzoyl peroxide (BPO) and an antibiotic is more efficacious and better tolerated than treatment with either component alone... The addition of hydrating excipients in the C/BPO HE formulation appears to improve patient tolerance and acceptance, which will likely help patients to comply with therapy.
Prospective, open-label, comparative study of clindamycin 1%/benzoyl peroxide 5% gel with adapalene 0.1% gel in Asian acne patients: efficacy and tolerability. [2009.03]
BACKGROUND: Used as individual agents, topical antibiotics and benzoyl peroxide are known to be effective in treatment of acne. Clindamycin phosphate 1% with benzoyl peroxide 5% (CDP/BPO) is a new combination gel, made by rationale, in that combination drug is more effective than either ingredients used alone. Adapalene 0.1% (ADA) is the third-generation retinoid, shown to be as effective as other topical retinoid with well tolerability. OBJECTIVES: To compare the efficacy and tolerability in combination of CDP/BPO in comparison with ADA in Asian patients with mild to moderate acne vulgaris... CONCLUSION: Combination formulation of CDP/BPO and ADA were shown to be both effective in decreasing total, inflammatory, and non-inflammatory lesion counts along with well tolerability in Asian patients with mild to moderate acne vulgaris.
Randomized study comparing the efficacy and tolerance of a lipophillic hydroxy acid derivative of salicylic acid and 5% benzoyl peroxide in the treatment of facial acne vulgaris. [2009.03]
BACKGROUND: New topical treatments for acne vulgaris are needed for patients who have tolerance problems with current treatments. AIMS: To compare the efficacy and tolerance of a lipophillic derivative of salicylic acid (lipo hydroxy acid or LHA) containing formulation and 5% benzoyl peroxide in subjects with acne vulgaris... CONCLUSION: These results suggest that the LHA formulation could be a treatment option to consider in mild to moderate acne vulgaris patients that are intolerant to benzoyl peroxide.
Community-based trial results of combination clindamycin 1%--benzoyl peroxide 5% topical gel plus tretinoin microsphere gel 0.04% or 0.1% or adapalene gel 0.1% in the treatment of moderate to severe acne. [2007.07]
Acne is characterized by different types of lesions at different stages of development... This study investigated the efficacy and safety of combination therapy with clindamycin 1%-BPO 5% topical gel plus tretinoin microsphere (RAM) gel 0.04% or 0.1% or adapalene (AP) gel 0.1% in moderate to severe acne.
Clinical Trials Related to Clinac (Benzoyl Peroxide Topical)
Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris [Completed]
This is a multi-center, randomized, double-blind, parallel group study with 12 weeks of
treatment of acne vulgaris. Efficacy and safety evaluations will be performed at Screening
(safety only), Baseline and Weeks 1, 2, 4, 8 and 12. All Investigator's Global Assessment
evaluators and lesion counters must be trained and approved by Galderma. The evaluator of a
subject should remain the same during the study.
The primary objective is to demonstrate the superiority in efficacy and assess safety of
adapalene/benzoyl peroxide topical gel (adapalene/benzoyl peroxide gel) versus adapalene
topical gel, 0. 1% (adapalene monad); benzoyl peroxide topical gel, 2. 5% (benzoyl peroxide
monad) and topical gel vehicle (gel vehicle) in the treatment of acne vulgaris for up to 12
weeks.
A Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris [Completed]
This is a multi-center, randomized, double-blind, parallel group study with 12 weeks of
treatment of acne vulgaris. Efficacy and safety evaluations will be performed at Screening
(safety only), Baseline and Weeks 1, 2, 4, 8 and 12. All Investigator's Global Assessment
evaluators and lesion counters must be trained and approved by Galderma. The evaluator of a
subject should remain the same during the study.
The primary objective is to demonstrate the superiority in efficacy and assess safety of
Adapalene/Benzoyl Peroxide Topical Gel (Adapalene/Benzoyl Peroxide Gel) versus Adapalene
Topical Gel, 0. 1% (Adapalene Monad); Benzoyl Peroxide Topical Gel, 2. 5% (Benzoyl Peroxide
Monad) and Topical Gel Vehicle (Gel Vehicle) in the treatment of acne vulgaris for up to 12
weeks.
A Long-Term Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris [Completed]
|
